NCT04883658View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 4, 2021

Primary Completion Date

July 20, 2021

Study Completion Date

August 19, 2021

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-348(2)

QD, PO

DRUG

CKD-828, D097, D337

QD, PO

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY